More than half of American adults 75 and older have already received one of the approved RSV vaccines, which creates an awkward problem for any late-entrant vaccine: the target population has pre-existing immunity. Clover’s Phase 2 data, released September 6, is built around exactly that obstacle. In 420 adults aged 60 to 85 enrolled in Australia, SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) produced 6-to-9-fold neutralizing antibody rises against RSV and 6-to-8-fold rises against hMPV at 28 days post-vaccination, with no drop-off in the oldest participants (75 and above) compared to those aged 60 to 74.
The finding that matters most for competitive positioning is the absence of immune interference. Adding PIV3 antigen in SCB-1033 did not blunt RSV or hMPV responses compared to the two-pathogen formulation, and the company is explicitly positioning both candidates as options for people who already received Arexvy, Abrysvo, or mRESVIA to restore and broaden protection. That framing shifts the clinical question from “does it work?” to “does it add coverage that single-pathogen RSV vaccines cannot?” Phase 2 immunogenicity data cannot answer that definitively, but the pattern is consistent enough with Phase 1 to make the argument credible.
Safety held up through the trial period. Solicited adverse events within seven days were mostly mild and resolved in about two days across both vaccine and placebo groups. There were no vaccine-related serious adverse events, no events of special interest, and no discontinuations. Separately, the company completed 2,000-liter commercial-scale bioreactor production of all three antigen components, which matters because manufacturing failures at scale have derailed protein-subunit programs before. Having that process validated before a pivotal trial removes one of the larger late-stage unknowns. The trial also captured an incidental signal: respiratory tract infection rates in vaccinated participants were roughly 62 percent lower than in placebo recipients within 28 days, though the study used adverse event reporting rather than PCR confirmation, so that number should be read as hypothesis-generating at best.
Clover says it will evaluate mid- and late-stage development plans and seek global partnership opportunities, which means no Phase 3 start date is announced. CDC data from February 2026 puts RSV vaccination coverage at 43 percent among adults 75 and older, leaving a meaningful unvaccinated fraction, but the commercial case for a three-pathogen combination ultimately rests on demonstrating that broader coverage translates to fewer hospitalizations, not just higher antibody titers. That question requires an outcomes-powered Phase 3, and the readiness of a potential partner to fund it is the real variable to watch.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
